Alyssa Hill

Alyssa Hill completed a Ph.D. in Microbiology in 2017. Her doctoral work focused on the biophysical properties of RNA and was supported by a Graduate Research Fellowship from the U.S. National Science Foundation (NSF). From 2017 to 2023, Alyssa carried out postdoctoral work at Eidgenössische Technische Hochschule (ETH) Zürich in Switzerland. Her projects tackled delivery challenges for nucleic acid therapeutics, particularly small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and ASO conjugates, with the support of the Novartis Research Foundation (FreeNovation Grant), the Swiss National Science Foundation (Spark Grant), and the Roche Innovation Center Copenhagen. Alyssa is a former McNair Scholar committed to achieving higher diversity, equity, and inclusion (DEI) in STEM, with prior awards from DEI initiatives such as Fix The Leaky Pipeline (ETH domain). Alyssa currently is Group Leader - Oligo Biology Drug Development. She leads in vitro screening and in vivo pharmacokinetics/pharmacodynamics work streams within the TransNAT and CureHeart consortia.